Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449695 | 0.82 | LMNA (0.42) | PTGER2RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL4447562 | 0.81 | ALDH1A1 (0.42) | PTGER2L3MBTL1 | |
| SCHEMBL13670576 | 0.80 | PTGER2 (0.39) | PTGER2HDAC1RIPK1HDAC8ADRB3 | |
| SCHEMBL29211080 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL29211140 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL29211089 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL29211135 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL8618795 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL21371750 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL28066940 | 0.77 | RIPK1 (0.52) | RIPK1LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | OXER1, ESRRA, NR5A1 | PTGER2 954/4885HDAC1 109/4885RIPK1 116/4885 |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | AK1, IRAK1, CNKSR1 | PTGER2 1094/4885HDAC1 499/4885RIPK1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.